Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I

##STR00001##

The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I

##STR00001##

The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Scleritine is used as a protective agent for cells against toxic agents, in particular chemical or physical agents. One or more embodiments relate to a dermatological and/or cosmetic composition, which protects the skin against toxic agents, characterized in that it comprises Scleritine in at least one excipient or vehicle adapted to a topical application. One or more embodiments concerns the pharmaceutical or cosmetic industry and more specifically the formulation of pharmaceutical or cosmetic compositions intended to protect cells against toxic agents.

Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.

A method of neutralizing or mitigating a drug-induced mitochondrial dysfunction or impairment for an individual, the method including providing to the individual an effective amount of a composition containing glycine or a functional derivative thereof and N-acetylcysteine or a functional derivative thereof. The drug-induced mitochondrial dysfunction or impairment is from at least one drug consumed by the individual selected from the group consisting of an anticonvulsant; a psychotropic other than an antipsychotic drug; an analgesic/anti-inflammatory drug other than acetaminophen; an antibiotic; an anti-arrhythmic drug; a steroid; a beta-blocker; and an immunization.

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to formula I:

##STR00001##

The use of these compounds as radio- and chemo-protectors is also described.

The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methylamino)methyl)propane-1-thiol. The compounds of this disclosure also relate to formula I:

##STR00001##

The use of these compounds as radio- and chemo-protectors is also described.